









Markets
/
Stocks
/
nasdaq-sln
/

Silence Therapeutics PLC

SLN

View Detailed Chart

6.170USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

874.23MMarket Cap

LossP/E TTM



Silence Therapeutics PLC

6.170

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

+0.16%

5 Days

-2.68%

1 Month

+11.78%

6 Months

+21.94%

Year to Date

-10.32%

1 Year

-67.27%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 7 analysts

BUY

Current Rating

30.500

Target Price

394.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Silence Therapeutics PLC

SLN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(5)

Buy(4)

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.100

Neutral

RSI(14)

53.724

Neutral

STOCH(KDJ)(9,3,3)

54.285

Neutral

ATR(14)

0.415

Low Volatility

CCI(14)

-9.820

Neutral

Williams %R

54.654

Neutral

TRIX(12,20)

0.314

Sell

StochRSI(14)

87.560

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

6.120

Buy

MA10

6.179

Sell

MA20

6.207

Sell

MA50

5.784

Buy

MA100

4.627

Buy

MA200

6.776

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.

Ticker SymbolSLN

CompanySilence Therapeutics PLC

CEOMr. Craig A. Tooman

Websitehttps://www.silence-therapeutics.com/